Latest Insider Transactions at Werewolf Therapeutics, Inc. (HOWL)
This section provides a real-time view of insider transactions for Werewolf Therapeutics, Inc. (HOWL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Werewolf Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Werewolf Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,853,000
+24.53%
|
$3,706,000
$2.21 P/Share
|
|
Jan 12
2022
|
Cynthia Seidel Dugan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,731
+11.28%
|
$119,193
$3.17 P/Share
|
|
Dec 30
2021
|
Reid Leonard Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,102
+50.0%
|
$14,102
$1.56 P/Share
|
|
Dec 15
2021
|
Reid Leonard Chief Operating Officer |
SELL
Open market or private sale
|
Indirect |
3,000
-1.2%
|
$39,000
$13.68 P/Share
|
|
Jun 16
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
9,285
+0.22%
|
$120,705
$13.37 P/Share
|
|
Jun 15
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
7,958
+0.19%
|
$95,496
$12.95 P/Share
|
|
Jun 14
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
306,055
+6.68%
|
$3,672,660
$12.75 P/Share
|
|
May 04
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
125,759
+3.8%
|
$2,012,144
$16.0 P/Share
|
|
May 04
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,062,239
+34.98%
|
-
|
|
May 04
2021
|
Ansbert Gadicke > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
245,000
+3.54%
|
$3,920,000
$16.0 P/Share
|
|
May 04
2021
|
Ansbert Gadicke > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,965,775
+33.17%
|
-
|
|
May 04
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,715,000
+25.3%
|
$27,440,000
$16.0 P/Share
|
|
May 04
2021
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,253,583
+50.0%
|
-
|
|
May 04
2021
|
Luke Evnin |
BUY
Open market or private purchase
|
Indirect |
150,799
+3.4%
|
$2,412,784
$16.0 P/Share
|
|
May 04
2021
|
Luke Evnin |
BUY
Conversion of derivative security
|
Indirect |
3,671,965
+32.14%
|
-
|
|
May 04
2021
|
Hbm Healthcare Investments (Cayman) Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
625,995
+50.0%
|
-
|
|
May 04
2021
|
Upmc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,097,756
+34.98%
|
-
|
|
May 04
2021
|
Longwood Fund Iii Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+12.97%
|
$4,000,000
$16.0 P/Share
|
|
May 04
2021
|
Longwood Fund Iii Gp, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,427,082
+34.98%
|
-
|
|
May 04
2021
|
Arkin Bio Ventures 2 L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+16.35%
|
$6,400,000
$16.0 P/Share
|
|
May 04
2021
|
Arkin Bio Ventures 2 L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,646,634
+34.98%
|
-
|
|
May 04
2021
|
Taiho Ventures LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
312,500
+13.12%
|
$5,000,000
$16.0 P/Share
|
|
May 04
2021
|
Taiho Ventures LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,756,409
+34.98%
|
-
|
|
May 04
2021
|
Sphera Global Healthcare Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
475,000
+37.61%
|
$7,600,000
$16.0 P/Share
|
|
May 04
2021
|
Sphera Global Healthcare Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
312,997
+50.0%
|
-
|
|
May 04
2021
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
800,000
+23.86%
|
$12,800,000
$16.0 P/Share
|
|
May 04
2021
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,752,787
+50.0%
|
-
|
|
May 04
2021
|
Alon Lazarus |
BUY
Open market or private purchase
|
Indirect |
400,000
+16.35%
|
$6,400,000
$16.0 P/Share
|
|
May 04
2021
|
Alon Lazarus |
BUY
Conversion of derivative security
|
Indirect |
1,646,634
+34.98%
|
-
|
|
May 04
2021
|
Sakae Asanuma Director |
BUY
Open market or private purchase
|
Indirect |
312,500
+13.12%
|
$5,000,000
$16.0 P/Share
|
|
May 04
2021
|
Sakae Asanuma Director |
BUY
Conversion of derivative security
|
Indirect |
1,756,409
+34.98%
|
-
|